Pregnancy outcome after cabergoline treatment in early weeks of gestation

Ricci, Elena; Parazzini, Fabio; Motta, Tiziano; Ferrari, Carlo; Colao, Annamaria; Clavenna, Antonio; Rocchi, Francesca; Gangi, Emanuela; Paracchi, Sandra; Gasperi, Maurizio; Lavezzari, M; Nicolosi, Anna Elisa; Ferrero, S.; Landi, Maria Luisa; Beck‐Peccoz, Paolo; Bonati, Maurizio

doi:10.1016/s0890-6238(02)00055-2

Cited by 147 publications

(93 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In animal models, DRD2-A inhibits pathologic angiogenesis in tumors (Basu et al 2004) by inactivating VEGFR2 signaling (Basu et al 2001). However, this type of medication has an acceptable safety profile and does not interfere with the normal establishment and progression of pregnancy (Robert et al 1996, Ricci et al 2002. We have previously used a well-established experimental endometriosis model to demonstrate that the DRD2-A cabergoline (Cb2) prevents the formation of typical endometriosis lesions by inhibiting angiogenesis (Novella-Maestre et al 2009).…”

Section: Introductionmentioning

confidence: 99%

The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

Delgado-Rosas¹,

Gómez²,

Ferrero³

et al. 2011

Reproduction

View full text Add to dashboard Cite

Implantation of a retrogradely shed endometrium during menstruation requires an adequate blood supply, which allows the growth of endometriotic lesions. This suggests that the development of endometriosis can be impaired by inhibiting angiogenesis. The growth of endometriotic foci is impaired by commercial oncological antiangiogenic drugs used to block vascular endothelial growth factor (VEGF) signaling. The dopamine agonist cabergoline (Cb2) inhibits the growth of established endometriosis lesions by exerting antiangiogenic effects through VEGFR2 inactivation. However, the use of ergot-derived Cb2 is associated with an increased incidence of cardiac valve regurgitation. To evaluate the potential usage of non-ergot-derived dopamine agonists for the treatment of human endometriosis, we compared the efficacy of quinagolide with that of Cb2 in preventing angiogenesis and vascularization in a heterologous mouse model of endometriosis. Nude mice whose peritoneum had been implanted with eutopic human endometrial fragments were treated with vehicle, 50 mg/kg per day oral Cb2, or 50 or 200 mg/kg per day quinagolide during a 14-day period. At the end of the treatment period, the implants were excised in order to assess lesion size, cell proliferation, degree of vascularization, and angiogenic gene expression. Neoangiogenesis was inhibited and the size of active endometriotic lesions, cellular proliferation index, and angiogenic gene expression were significantly reduced by both dopamine agonists when compared with the placebo. Given that Cb2 and quinagolide were equally effective in inhibiting angiogenesis and reducing lesion size, these experiments provide the rationale for pilot studies to explore the use of non-ergot-derived dopamine agonists for the treatment of endometriosis in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

Delgado-Rosas¹,

Gómez²,

Ferrero³

et al. 2011

Reproduction

View full text Add to dashboard Cite

show abstract

“…Bromocriptine is the preferred dopamine agonist for prolactinoma during pregnancy, but since it crosses the placenta, it should not be continued if not necessary (151). Although the number of pregnancies is smaller in the studies, similar results are obtained with cabergoline (139,(152)(153)(154)(155)(156)(157)(158). Cabergoline may be an effective and safe alternative to bromocriptine during pregnancy with a good tolerance (159).…”

Section: Prolactinomas and Pregnancymentioning

confidence: 66%

Pregnancy and pituitary disorders

Karaca¹,

Tanrıverdi²,

Ünlühızarcı³

et al. 2010

European Journal of Endocrinology

164

View full text Add to dashboard Cite

Major hormonal changes emerge during pregnancy. The pituitary gland is one of the most affected organs with altered anatomy and physiology. The pituitary gland is enlarged as a result of lactotroph hyperplasia. Due to physiological changes in the pituitary and target hormone levels, binding globulins, and placental hormones, hormonal evaluation becomes more complex in pregnant women. As a consequence of physiological hormonal changes, the evaluation of pituitary functions in pregnant women is quite different from that done in the prepregnant state. Pituitary adenomas may cause problems by their hormone secretion that affects the mother and the fetus besides causing an increased risk of tumor growth. Furthermore, diagnosis, course, and treatment of pituitary diseases point out differences. The changes in anatomy and physiology of the pituitary gland during pregnancy are reviewed. Pituitary disorders namely Cushing's disease; acromegaly; prolactinoma; TSH-secreting, gonadotropin-producing, and clinically nonfunctioning adenomas; craniopharyngioma; and Sheehan's syndrome, which is one of the most common causes of hypopituitarism, lymphocytic hypophysitis, and hypopituitarism, in relation to pregnancy are discussed. Being aware of all this information will prevent any serious problems which mother and child will be exposed to.

show abstract

“…Most data on the safety of the use of cabergoline during pregnancies in women treated with cabergoline from women with prolactinomas [19,20].…”

Section: Safety Aspects Of Using Cabergoline During Pregnancymentioning

confidence: 99%

Cabergoline use for cushing’s disease during pregnancy: Mini review

Almalki¹

2017

Clin Res Trials

View full text Add to dashboard Cite

Cushing disease (CD) rarely occurs during pregnancy and is associated with significant maternal and fetal comorbidity. The usual first-line treatment is surgery, and when surgery, is not feasible, medical therapy is usually considered. However, treatment of CD during pregnancy has consisted of conservative management without specific treatment. Cabergoline, is the drug of choice for treating hyperprolactinemia, is also found to be effective in reducing hypercortisolism in CD and used off-label for treating CD during pregnancy. Data concerning the safety of cabergoline use in pregnancy did not show any potential adverse effect of the drug on pregnancy outcome.

show abstract

Pregnancy outcome after cabergoline treatment in early weeks of gestation

Cited by 147 publications

References 7 publications

The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

Pregnancy and pituitary disorders

Cabergoline use for cushing’s disease during pregnancy: Mini review

Contact Info

Product

Resources

About